ABSTRACT:

Hypertension is a common chronic disease that is closely associated with certain serious health issues like retinopathy. Typically, retinopathy is referred to as the damage or loss of the light-sensitive layer of tissue at the back of the eye due to prolonged high pressure in one’s blood. If one is suffering from high blood pressure, it may ravage the blood vessels within the retina. These ravages lead to changes within the structure of the retina hence classified into different stages Non-proliferative Retinopathy: An early stage that shows minimal changes within the retina, together with microaneurysms, and retinal hemorrhages. The advanced stage abnormal new blood vessels proliferate on the retina leading to further severe complications including total blindness. Patients may not show any kind of visible signs in the early stages. But as the disease advances, some warning signs could comprise: Blurred vision, Abrupt loss of vision, Difficulty in seeing at night Visual distortions Diagnosis is normally clinical with a complete eye examination to include: – Fundoscopy – Visual acuity tests – Imaging modalities like optical coherence tomography (OCT) It is, therefore, very important to control hypertension so as to prevent or delay the progression of retinopathy in a particular individual. The treatment could be through: Lifestyle changes (dietary, exercising, quitting smoking) Medications to control blood pressure In advanced cases, laser therapy or operation for vitrectomy may have to be done as treatment for proliferative retinopathy caused by hypertension. Retinopathy due to hypertension is a very serious condition that reinforces the need for regular monitoring and proper control of blood pressure. If detected early and intervened upon early, it could significantly cut down the risk of loss of vision and enhance the general health outcomes if one has hypertension, proper and timely treatment.

KEYWORDS :

Hypertension, retinopathy, Solar Retinopathy.

REFERENCES :

1) Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526, 1984
2) UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
3) Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889–896, 2000
4) M, Byrd-Holt DD: Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care 21:1230–1235, 1998
5) Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 (Suppl. 2): B54– B64, 2000
6) Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532, 1984
7) UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 12:352:854–865, 1998
8) affner SM, Fong D, Stern MP, Pugh JA, Hazuda HP, Patterson JK, van Heuven WA, Klein R: Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes 37:878–884, 1988
9) Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Zipes DP, Libby P, Bonow RO, editors. Braunwald’s heart disease. 7th ed. Philadelphia, PA: Elsevier Sanders; 2005. p. 959–1012.
10) Wallach R, Karp RB, Reves JG, et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 1980; 46:559–65
11) Weinstein GS, Zabetakis PM, Clavel A, et al. The renin–angiotensin system is not responsible for hypertension following coronary artery bypass grafting. Ann Thorac Surg 1987;43:74–7.
12) Gurubhagavatula I, Palevsky HI. Pulmonary hypertension in systemic autoimmune disease. Rheum Dis Clin North Am 1997;23:365-94.
13) Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17: 17-33.
14) Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73:37-45.
15) Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998;114:195S-9S.
16) Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
17) Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
18) Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92
19) Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med 2000;132:227-32
20) Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996;109:380-6.